EUVIMEDEUVIMED entdecken
Crossref

Optimizing Nefopam Dosing Strategies and Administration Timing while Assessing their Long-Term Influence on Recovery Trajectories and Graft Success

Zahra Raza Ghafari, Ghassan Kloub, Ramesh Srigiri, Rasha Maryam, Rama Krishna2

International Journal of Anesthetics and Anesthesiology · 24.03.2026 · 13 (1) · 1-4

DOI: 10.23937/2377-4630/1410193 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Anesthetics and Anesthesiology, online erschienen am 24.03.2026. Verfasst von Zahra Raza Ghafari und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nefopam is analgesic drug which is a non-opioid, non-nonsteroidal and anti-inflammatory that inhibits the reuptake of serotonin, norepinephrine, and dopamine. It is widely used as an adjuvant for pain. Nefopam has multiple mechanisms therefore it is consider both analgesic and anti-hyperalgesic properties, which is particularly interesting when considering long-term sensitization and recovery. Analgesic drug is Nefopam a centrally acting non-opioid has emerged as a good candidate for inclusion in multimodal analgesia. Nefopam exerts anti-nociceptive effects by inhibiting the synaptosomal reuptake of serotonin, dopamine, and norepinephrine. Nefopam has been reported to be effective in postoperative pain control with an opioid-sparing effect.However, nefopam itself can induce PONV according to some studies and there is relatively little information on the effect of nefopam on PONV when used in combination with fentanyl. Researches revealed that the drug is a centrally acting, non-opioid analgesic and N-methyl-D-aspartate (NMDA) receptor antagonist which inhibits voltage-sensitive sodium channels. Nefopam has been demonstrated as an anti allodynic effects in a neuropathic pain model and the ATP-sensitive potassium channel may be involved. In a rat model study of pain induced by formalin, intrathecal nefopam significantly increased serotonin and norepinephrine levels and it reduced the release of glutamate in the spinal cord. Nausea, vomiting, sweating, dizziness, drowsiness, and tachycardia are known adverse effects of nefopam. Nefopam should be administered with slowly intravenous infusion as a single, 20-mg dose, followed by a continuous infusion of 60 to 120 mg/day. Neuropathic Pain Symptom Inventory (NPSI-T) score is used to assess the Neuropathic pain. This tool utilizes a self-administered questionnaire to evaluate the positive symptoms of neuropathic pain. Therefore, the aim of this study is to optimize the nefopam dose strategies and administration timing while assessing their long-term influence on recovery trajectories and graft success with other drugs.

Zitieren

APA

Ghafari, Z. R., Kloub, G., Srigiri, R., Maryam, R., & Krishna2, R. (2026). Optimizing Nefopam Dosing Strategies and Administration Timing while Assessing their Long-Term Influence on Recovery Trajectories and Graft Success. International Journal of Anesthetics and Anesthesiology, 13(1), 1-4. https://doi.org/10.23937/2377-4630/1410193

Vancouver

Ghafari ZR, Kloub G, Srigiri R, Maryam R, Krishna2 R. Optimizing Nefopam Dosing Strategies and Administration Timing while Assessing their Long-Term Influence on Recovery Trajectories and Graft Success. International Journal of Anesthetics and Anesthesiology. 2026;13(1):1-4. doi:10.23937/2377-4630/1410193

BibTeX
@article{Ghafari2026,
  author = {Ghafari, Zahra Raza and Kloub, Ghassan and Srigiri, Ramesh and Maryam, Rasha and Krishna2, Rama},
  title = {Optimizing Nefopam Dosing Strategies and Administration Timing while Assessing their Long-Term Influence on Recovery Trajectories and Graft Success},
  journal = {International Journal of Anesthetics and Anesthesiology},
  year = {2026},
  volume = {13},
  number = {1},
  pages = {1--4},
  doi = {10.23937/2377-4630/1410193}
}
Kostenlos starten →